Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chinese Patent Office
AstraZeneca
Merck
Harvard Business School
Colorcon
Citi
Daiichi Sankyo
Julphar

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,902,744

« Back to Dashboard

Which drugs does patent 6,902,744 protect, and when does it expire?

Patent 6,902,744 protects BYETTA and is included in one NDA.

This patent has sixty-eight patent family members in nineteen countries.
Summary for Patent: 6,902,744
Title: Exendin agonist formulations and methods of administration thereof
Abstract:Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Inventor(s): Kolterman; Orville G. (Poway, CA), Young; Andrew A. (La Jolla, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:09/889,330
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,902,744
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,902,744

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Ab BYETTA exenatide synthetic INJECTABLE;SUBCUTANEOUS 021773-001 Apr 28, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Ab BYETTA exenatide synthetic INJECTABLE;SUBCUTANEOUS 021773-002 Apr 28, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,902,744

PCT Information
PCT FiledJanuary 14, 2000PCT Application Number:PCT/US00/00902
PCT Publication Date:July 20, 2000PCT Publication Number: WO00/41546

Non-Orange Book US Patents Family Members for Patent 6,902,744

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,407,932 Methods for glucagon suppression using modified exendins ➤ Sign Up
6,872,700 Methods for glucagon suppression ➤ Sign Up
7,399,489 Exendin analog formulations ➤ Sign Up
7,906,146 Lyophilized formulations of exendins and exendin agonist analogs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Moodys
Chubb
Cantor Fitzgerald
Cipla
Deloitte
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.